Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class ii invariant chain

The orthodox role of the invariant chain (CD74; Ii) is in antigen presentation to CD4+ T cells, but enhanced CD8+ T cells responses have been reported after vaccination with vectored viral vaccines encoding a fusion of Ii to the antigen of interest. In this study we assessed whether fusion of the ma...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 9; no. 6; p. e100538
Main Authors Spencer, Alexandra J, Cottingham, Matthew G, Jenks, Jennifer A, Longley, Rhea J, Capone, Stefania, Colloca, Stefano, Folgori, Antonella, Cortese, Riccardo, Nicosia, Alfredo, Bregu, Migena, Hill, Adrian V S
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 19.06.2014
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The orthodox role of the invariant chain (CD74; Ii) is in antigen presentation to CD4+ T cells, but enhanced CD8+ T cells responses have been reported after vaccination with vectored viral vaccines encoding a fusion of Ii to the antigen of interest. In this study we assessed whether fusion of the malarial antigen, ME-TRAP, to Ii could increase the vaccine-induced CD8+ T cell response. Following single or heterologous prime-boost vaccination of mice with a recombinant chimpanzee adenovirus vector, ChAd63, or recombinant modified vaccinia virus Ankara (MVA), higher frequencies of antigen-specific CD4+ and CD8+ T cells were observed, with the largest increases observed following a ChAd63-MVA heterologous prime-boost regimen. Studies in non-human primates confirmed the ability of Ii-fusion to augment the T cell response, where a 4-fold increase was maintained up to 11 weeks after the MVA boost. Of the numerous different approaches explored to increase vectored vaccine induced immunogenicity over the years, fusion to the invariant chain showed a consistent enhancement in CD8+ T cell responses across different animal species and may therefore find application in the development of vaccines against human malaria and other diseases where high levels of cell-mediated immunity are required.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interests: AVSH is a named inventor on WO/2008/122811-Adenoviral vectors encoding a pathogen or tumour antigen and WO/2008/122769-Adenoviral vector encoding malaria antigen. S. Colloca, AF, RC, and AN are named inventors on patent application WO 2005071093 (A3)-Chimpanzee adenovirus vaccine carriers. Authors from Okairos were employees of and/or share holders in Okairos, this does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
Conceived and designed the experiments: AJS MGC MB AVSH. Performed the experiments: AJS RJL JAJ SCapone. Analyzed the data: AJS. Contributed reagents/materials/analysis tools: SC RC SC AF AN. Wrote the paper: AJS MGC.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0100538